Energy and Commerce Committee

Health


Bipartisan E&C Committee Leaders Request Info on Lagging Approvals for Complex Generic Drugs

01.17.2020

WASHINGTON, DC – Bipartisan Energy and Commerce leaders sent a letter to U.S. Food and Drug Administration (FDA) Commissioner Stephen Hahn, M.D. to request information on the FDA's process for approving complex generic drugs.

The letter was sent by Energy and Commerce Republican Leader Greg Walden (R-OR), Chairman Frank Pallone, Jr. (D-NJ), Health Subcommittee Republican Leader Michael Burgess M.D. (R-TX), Health Subcommittee Chairwoman Anna G. Eshoo (D-CA), Oversight and Investigations Subcommittee Republican Leader Brett Guthrie (R-KY), and Oversight and Investigations Subcommittee Chair Diana DeGette (D-CO).

"We are interested in identifying ways...

News

Letter to FDA on Lagging Approvals for Complex Generic Drugs

01.17.2020

Excerpt: "We are interested in identifying ways to help reduce the costs of health care for patients, including the costs of prescription drugs. Generic versions of brand-name drugs provide substantial cost savings for patients and third-party payers and account for nine out of ten prescriptions filled in the U.S.," the bipartisan Committee members wrote to FDA.

CLICK HERE to read the letter to FDA.

Letter

Bipartisan E&C Committee Leaders Request GAO Review of Indian Health Service Infrastructure

01.17.2020

WASHINGTON, DC – Energy and Commerce Chairman Frank Pallone, Jr. (D-NJ), Republican Leader Greg Walden (R-OR), Rep. Raul Ruiz, M.D. (D-CA) and Rep. Markwayne Mullin (R-OK) sent a letter to the U.S. Government Accountability Office (GAO) today requesting a review of the impact the Indian Health Service’s (IHS) aging infrastructure has on patient access to quality health care and positive health outcomes.

The IHS is responsible for providing health care to approximately 2.56 million American Indian and Alaska Native people located across the country at 170 IHS and tribally run...

Press Release

Health

Jurisdiction


The health sector broadly, including private and public health insurance (Patient Protection and Affordable Care Act, Medicare, Medicaid, CHIP); biomedical research and development; hospital construction; mental health; health information technology, privacy, and cybersecurity; medical malpractice and medical malpractice insurance; the 340B drug discount program; the regulation of food, drugs, and cosmetics; drug abuse; the Department of Health and Human Services; the National Institutes of Health; the Centers for Disease Control; Indian Health Service; and all aspects of the above-referenced jurisdiction related to the Department of Homeland Security.